Atomoxetine treatment and ADHD-related difficulties as assessed by adolescent patients, their parents and physicians

被引：15

作者：

Dittmann R.W. ^{[1
]}

Wehmeier P.M. ^{[2
]}

Schacht A. ^{[2
]}

Minarzyk A. ^{[2
]}

Lehmann M. ^{[2
]}

Sevecke K. ^{[3
]}

Lehmkuhl G. ^{[3
]}

机构：

[1] Department of Child and Adolescent Psychiatry, Central Institute of Mental Health Mannheim, University of Heidelberg

[2] Lilly Deutschland GmbH, Medical Department, Bad Homburg

[3] Department of Child and Adolescent Psychiatry, University of Cologne

来源：

Child and Adolescent Psychiatry and Mental Health | / 3卷 / 1期

关键词：

ADHD Symptom; Atomoxetine; Oppositional Defiant Disorder; Last Observation Carry Forward; Combine Subtype;

D O I：

10.1186/1753-2000-3-21

中图分类号：

学科分类号：

摘要：

Background: The degree of ADHD-related difficulties - reflecting overall impairment, social functioning, and quality of life - may be perceived differently by adolescent patients, parents and physicians. The primary aim of this study was to investigate ADHD-related difficulties during atomoxetine treatment, as perceived by the three different raters. Secondary objectives focused on effectiveness and tolerability of atomoxetine treatment in a population of adolescent patients with ADHD. Methods: Adolescents with ADHD, aged 12-17 years, received open-label atomoxetine (0.5-1.2 mg/kg/day) up to 24 weeks. ADHD-related difficulties at various times of the day were rated using the Global Impression of Perceived Difficulties (GIPD) instrument. Inter-rater agreement was analyzed using Cohen's Kappa with 95% confidence intervals (95% CI). ADHD-Rating Scale (ADHD-RS) and Clinical Global Impression Severity (GGI-S) scores were assessed by the investigator; and spontaneous adverse events, vital signs and laboratory parameters were collected for tolerability assessments. Results: 159 patients received atomoxetine. Patients' baseline mean GIPD total ratings were significantly lower than parents' and physicians' scores (12.5 [95%CI 11.6;13.5] vs. 17.2 [16.2;18.2] and 18.8 [17.8;19.8]). For all raters, GIPD scores significantly improved over time. Changes were greatest within the first two weeks. Kappa coefficients varied between 0.186 [0.112;0.259] and 0.662 [0.529;0.795], with strongest agreements between parent and physician assessments, and significant improvements of patient/physician agreements over time (based on 95% CIs). ADHD-RS and CGI-S scores significantly improved over the course of the study (based on 95% CIs). Tolerability results were consistent with earlier reports. Conclusion: ADHD-related difficulties were perceived differently by the raters in this open-label trial, but consistently improved during atomoxetine treatment. The GIPD instrument appeared sensitive to treatment-related change. These primarily quantitative findings may guide future studies to more systematically investigate the clinical and practical relevance of the differences observed. Additionally, in order to further validate these results, placebo- and comparator-controlled trials are recommended as well as inclusion of healthy controls and other patient populations. Trial Registration: Clinical Trial Registry: ClinicalTrials.gov: NCT00191737. © 2009 Dittmann et al; licensee BioMed Central Ltd.

引用

共 50 条

[41]

March J., Karayal O., Chrisman A., The Pediatric Adverse Event Rating Scale, The Scientific Proceedings of the 2007 Annual Meeting of the American Academy of Child and Adolescent Psychiatry: 23-28 October 2007

[42]

Boston, (2007)

[43]

Wehmeier P.M., Schacht A., Lehmann M., Dittmann R.W., Silva S.G., March J.S., Emotional well-being in children and adolescents treated with atomoxetine for attention-deficit/hyperactivity disorder: Findings from a patient, parent and physician perspective using items from the Pediatric Adverse Event Rating Scale (PAERS), Child Adolesc Psychiatry Ment Health, 2, (2008)

[44]

Escobar R., Soutullo C.A., Hervas A., Gastaminza X., Polavieja P., Gilaberte I., Worse quality of life for children with newly diagnosed attention-deficit/hyperactivity disorder, compared with asthmatic and healthy children, Pediatrics, 116, (2005)

[45]

Newcorn J.H., Spencer T., Biederman J., Milton D., Michelson D., Atomoxetine treatment in children and adolescents with ADHD and comorbid oppositional defiant disorder, J Am Acad Child Adolesc Psychiatry, 44, pp. 240-248, (2005)

[46]

Steele M., Jensen P.S., Quinn D.M.P., Remission versus response as the goal of therapy in ADHD: A new standard for the field?, Clin Ther, 28, pp. 1892-1907, (2006)

[47]

Biederman J., Faraone S.V., Mick E., Williamson S., Wilens T.E., Spencer T.J., Weber W., Jetton J., Kraus I., Pert J., Zallen B., Clinical correlates of ADHD in females: findings from a large group of girls ascertained from pediatric and psychiatric referral sources, J Am Acad Child Adolesc Psychiatry, 38, pp. 966-975, (1999)

[48]

Newcorn J.H., Halperin J.M., Jensen P.S., Abikoff H.B., Arnold L.E., Cantwell D.P., Conners C.K., Elliott G.R., Epstein J.N., Greenhill L.L., Hechtman L., Hinshaw S.P., Hoza B., Kraemer H.C., Pelham W.E., Severe J.B., Swanson J.M., Wells K.C., Wigal T., Vitiello B., Symptom profiles in children with ADHD: effects of comorbidity and gender, J Am Acad Child Adolesc Psychiatry, 40, pp. 137-146, (2001)

[49]

Linden M., Postmarketing surveillance of psychotherapeutic medications. A challenge for the 1990s, Psychopharmacol Bull, 29, pp. 51-56, (1993)

[50]

Osterheider M., Dittmann R.W., Linden M., Das Nebenwirkungsspektrum von Fluoxetin [The adverse event profile of fluoxetine], Psychopharmakotherapie Suppl, 5, pp. 39-42, (1997)

← 1 2 3 4 5 →